title: [Treatment of lung cancer in the elderly].
abstract: Elderly patients form an increasing proportion of the lung cancer population. However, they are poorly represented in clinical trials. The published studies are generally phase II trials on highly selected small numbers of patients. Applying these trials to clinical practice is therefore difficult and this is compounded by the fear of increased treatment toxicity in elderly patients. In the event of organ failure (respiratory, cardiac or other organ failure), where conventional therapy is not possible, there are a number of alternative options: radiotherapy for inoperable limited non-small-cell-lung cancer, chemotherapy without platinum for those with more extensive disease or with analogues of platinum for small-cell-lung-cancer. Finally, adjunctive therapy with haematopoietic-cell growth factors or cytoprotectors may allow full doses of treatment to be delivered whilst limiting toxicity. More studies in elderly patients, with larger numbers, are needed to develop more rational therapeutic strategies. We present here some studies of reference and the most recent publications on this subject.
authors.affiliation: Service de Pneumologie, Hospices Civils de Lyon, CH Lyon Sud, Pierre Bénite.
authors.forename: S
authors.initials: S
authors.lastname: Diab
authors.forename: L
authors.initials: L
authors.lastname: Geriniere
authors.forename: C
authors.initials: C
authors.lastname: Carrie
authors.forename: P J
authors.initials: PJ
authors.lastname: Souquet
mesh_terms: D000367:Age Factors; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000628:therapy*; D018288:Carcinoma, Small Cell / Q000628:therapy*; D002985:Clinical Protocols; D006801:Humans; D008175:Lung Neoplasms / Q000628:therapy*
chemical_list: D000970:Antineoplastic Agents